Temsirolimus and Vorinostat in Treating Patients With Metastatic Prostate Cancer
Status:
Terminated
Trial end date:
2016-08-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Temsirolimus and vorinostat may stop the growth of tumor cells by blocking some of
the enzymes needed for cell growth. Giving temsirolimus together with vorinostat may kill
more tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of
temsirolimus and vorinostat in treating patients with metastatic prostate cancer.
Phase:
Phase 1
Details
Lead Sponsor:
Roswell Park Cancer Institute
Collaborators:
Merck Sharp & Dohme Corp. National Cancer Institute (NCI)